A clinical trial of STI 1557 for the prevention of Omicron SARS-CoV-2 virus infection
Latest Information Update: 12 Dec 2022
At a glance
- Drugs STI 1557 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 12 Dec 2022 New trial record
- 06 Dec 2022 According to a Sorrento Therapeutics media release, company has received clearance from the US FDA to initiate this trial.